OpenAI launches GPT-Rosalind AI to speed up drug discovery and scientific research workflows.

OpenAI has introduced GPT-Rosalind, a new AI model designed specifically for scientific research and drug discovery. This model enhances understanding of chemistry, protein engineering, and genomics to help scientists accelerate the drug development process, which currently takes 10 to 15 years. GPT-Rosalind is available for qualified users via ChatGPT, Codex, and API, with collaborations underway with major pharma companies like Amgen and Moderna. The AI aims to improve efficiency and enable researchers to explore new possibilities and hypotheses faster, potentially transforming healthcare innovation.